Get started
Author

Sateesh Kumar Nagumantry

Observed names: S. K. Nagumantry, S. Nagumantry, S.K. Nagumantry, Sateesh K Nagumantry, Sateesh K. Nagumantry, Sateesh Nagumantry
ORCID: 0000-0002-4204-5317
Observed ORCID: 0000-0002-4204-5317
OpenAlex ID: A5059496270
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
2023 · Jad Othman, Ing S. Tiong, et al. · Blood · 81
PDF
Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria
2023 · Richard J. Kelly, Matthew Holt, et al. · Blood · 59
Real‐world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
2024 · Morag Griffin, Richard Kelly, et al. · American Journal of Hematology · 47
PDF
Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential
2024 · Chunye Zhang, Ellen Stelloo, et al. · Leukemia · 27
PDF
CREST ‐ UK : Real‐world effectiveness, safety and outpatient delivery of CPX ‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UK
2024 · Priyanka Mehta, Victoria Campbell, et al. · British Journal of Haematology · 20
PDF
Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study
2025 · Joanna A. Krupka, Ilias Moutsopoulos, et al. · Journal of Clinical Oncology · 14
Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria
2022 · Morag Griffin, Petra Muus, et al. · Blood · 13
PDF
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study
2024 · Anna Santarsieri, Emily Mitchell, et al. · The Lancet Oncology · 12
PDF
Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
2022 · Anna Santarsieri, Emily Mitchell, et al. · Blood · 9
Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp
2021 · Anna Santarsieri, Katherine Sturgess, et al. · Blood · 8
A Rare Case of Severe Hemolytic Anemia and Pulmonary Embolism Secondary to Mycoplasma pneumoniae Infection
2022 · Aravind Sunderavel Kumaravel Kanagavelu, Sateesh K. Nagumantry, et al. · Journal of Medical Cases · 7
PDF
Oral iptacopan for paroxysmal nocturnal haemoglobinuria—First real‐world experience
2025 · Richard J. Kelly, Austin G. Kulasekararaj, et al. · British Journal of Haematology · 6
R-DA-EPOCH Treatment Is Highly Effective Therapy for Primary Mediastinal Large B-Cell Lymphoma: A Real-World Multi-Centre Retrospective Evaluation
2022 · Anna Santarsieri, Rory Bennett, et al. · Blood · 6
Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy
2022 · Jad Othman, Ing S Tiong, et al. · Blood · 4
Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious
2019 · Anna Santarsieri, Katherine Sturgess, et al. · Blood · 4
The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell Lymphoma
2025 · Joanna A Krupka, Ilias Moutsopoulos, et al. · medRxiv · 3
First cases of danicopan use in adolescent patients with paroxysmal nocturnal haemoglobinuria
2025 · Matthew Holt, Richard Kelly, et al. · British Journal of Haematology · 2
PDF
Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies
2025 · Thomas LeBlanc, Amir Ali, et al. · Blood · 1
PDF
Falsely low glycosylated haemoglobin levels probably secondary to hypersplenism in a patient with diabetes mellitus
2024 · Guy Hayakawa, Maya M Leibowitz, et al. · BMJ Case Reports · 1
PDF
Replacing procarbazine with dacarbazine in escalated BEACOPP reduces clinical toxicity with no loss of efficacy yet protects stem cells from excess somatic mutational damage
2023 · A. Santarsieri, E. Mitchell, et al. · Hematological Oncology · 1
PDF
Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom
2022 · Richard Kelly, Matthew Holt, et al. · Blood · 1
P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity
2022 · Anna Santarsieri, Katherine Sturgess, et al. · HemaSphere · 1
Primary intestinal follicular lymphoma in a patient with very vague abdominal symptoms
2015 · Fotini Debonera, Sateesh Nagumantry, et al. · Endoscopy · 1
PDF
Clinical Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria
2026 · Matthew Holt, Richard J. Kelly, et al. · American Journal of Hematology
PDF
A Case of Metastatic Spinal Cord Compression in a Patient With Coexisting Chronic Lymphocytic Leukemia and Colon Cancer
2025 · Kasim Abbas, Sateesh Nagumantry · Cureus
PDF
Works count: 35
Citation count: 328
H-index: 9
I10-index: 8
Year
Topic
Type